Study Name |
|
My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents |
ClinicalTrials.gov Identifier (if applicable) |
|
NCT02091141 |
Study Center |
Institution Name |
|
Science 37 Inc. |
Institution Address |
|
5875 Green Valley Circle, Suite 100 |
City |
|
Culver City |
State |
|
California |
Zip Code |
|
90230 |
Phone |
|
(720) 207-8363 |
Website |
|
https://www.science37.com/ |
Study Contacts |
Principal Investigator |
|
David Chan, MD |
P.I. Phone |
|
(213) 529-0657 |
P.I. Email |
|
mypathway@science37.com |
Study Coordinator |
|
Jade Yen |
Study Coordinator Phone |
|
(213) 529-0657 |
Study Coordinator Email |
|
jade@science37.com |
OVERVIEW – in layman’s terms (150 words max) |
|
This open-label study is looking at targeted therapies in patients with advanced cancer for whom there is no available, beneficial treatment. |
Enrollment |
|
This study is currently recruiting participants. |
Study Start Date |
|
04/01/2014 |
Estimated Completion Date |
|
08/01/2019 |
Purpose of the Study – in Layman’s Terms (use the “+” to add more list items) |
|
- This research study focuses on targeted therapies for people diagnosed with metastatic cancer.
- Targeted therapy is a newer type of cancer treatment based on specifically targeting genetic mutations (abnormalities) found in a tumor.
- This research study explores multiple investigational medications and their effect on specific mutations found in tumors.
- The goal of this research study is to find out how well the investigational medications may work to treat metastatic cancer with known mutations.
|
Inclusion Criteria – Patients Must: |
|
- At least 18 years of age or older.
- Live in the state of California.
- Currently diagnosed with advanced or metastatic cancer.
- Received prior anti-cancer treatment.
|
REQUIRED TESTS PRIOR TO BEGINNING STUDY TREATMENT – in layman’s terms |
|
- Molecular/genetic testing
|